What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval? Sagar Lonial, MD, FACP vs. Peter Voorhees, MD vs. Kenneth Anderson, MD #ASH20
29:57
Multiple Myeloma
What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval? Sagar Lonial, MD, FACP vs. Peter Voorhees, MD vs. Kenneth Anderson, MD #ASH20
Multiple Myeloma Similar Videos
Similar Videos
-
Virtual Challenging Case Clinic: Multiple Myeloma_Optimal Induction and Maintenance Therapies_Amrita Krishnan, MD
47:14
-
Racial Differences in Clinical Trial Participation and Therapeutic Outcomes with a Focus on Multiple Myeloma_Craig Emmitt Cole, MD
51:36
-
Virtual Challenging Case Clinic: Multiple Myeloma_Updates from ASH_Peter Voorhees, MD
56:33